Drug Profile
BOS 172722
Alternative Names: BOS-172722Latest Information Update: 20 Oct 2021
Price :
$50
*
At a glance
- Originator Institute of Cancer Research
- Developer Boston Pharmaceuticals
- Class Antineoplastics; Diamines; Phenyl ethers; Pyridines; Pyrimidines; Small molecules; Triazoles
- Mechanism of Action TTK protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 18 Mar 2021 Discontinued - Phase-I for Solid tumours (Late-stage disease, Monotherapy) in United Kingdom (PO) before March 2021 (Boston Pharmaceuticals pipeline, March 2021)
- 16 Mar 2021 Boston Pharmaceuticals completes a phase I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Monotherapy) in United Kingdom (PO) (NCT03328494)
- 28 Nov 2020 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in United Kingdom (PO, Capsule)